|
EpiCept Gets Fast-Track Designation for Neuropathic Pain Product
EpiCept’s neuropathic pain product AmiKet has received fast-track designation after the agency waived several non-clinical toxicology studies planned in support of the drug.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
Report Predicts More Use of Drug Special Designations in 2013FDA, EU Likely to Increase Use of Special Designations to Speed Approvals in 2013, Tufts SaysPossible FDA Approval of New Pain Drug Using Other Drug’s Data May Save Struggling NeurogesXGilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
|
Subscribe
Archives